欢迎登录材料期刊网

材料期刊网

高级检索

在可降解AZ31B镁合金心血管支架表面成功制备了携带雷帕霉素的聚乳酸--聚三亚甲基碳酸酯(PLA--PTMC)共聚物涂层, 评价了涂层的表面形貌、降解性能、血液相容性和药物释放性能. 结果表明, PLA--PTMC共聚物作为载药涂层具有良好的柔韧性, 表面均匀、光滑, 降解周期超过1个月, 血液相容性良好. 涂层具有缓释雷帕霉素的功能, 释药周期超过1个月, 可在内膜增生期内有效抑制支架植入后再狭窄的发生, 满足冠脉支架表面载药层的使用要求.

The sirolimus--releasing PLA--PTMC coating was successfully prepared on the biodegradable AZ31B magnesium alloy coronary stents. The surface morphology, degradability, biocompatibility and drug release characteristic of the coating were also evaluated. The results indicated that PLA--PTMC used as the drug elution coating showed good flexibility with smooth and uniform surface, the degradation period was over one month, and the biocompatibility was excellent. The drug--loaded coating had releasing function of sirolimus and the releasing time was more than one month, which could effectively inhibit the restenosis during the period of intima hypertrophy. The sirolimus--releasing PLA--PTMC coating showed potential to be used as a new type of coronary stent coating. 

参考文献

[1]
[2]
[3]
[4]
[5]
上一张 下一张
上一张 下一张
计量
  • 下载量()
  • 访问量()
文章评分
  • 您的评分:
  • 1
    0%
  • 2
    0%
  • 3
    0%
  • 4
    0%
  • 5
    0%